We describe the first reported case of anaerobic sepsis due to Bacteroides fragilis with simultaneous resistance to metronidazole, b-lactams, b-lactam/b-lactamase inhibitors, carbapenems, macrolides, and tetracyclines. Microbiological cure and clinical improvement was achieved with linezolid therapy, an agent that may be useful for the treatment of multidrug-resistant anaerobic infections.
ceptibility testing of the isolate by the British Society for Antimicrobial Chemotherapy disc diffusion method revealed no zone of inhibition to penicillin (1.5 units), amoxicillin/clavulante (3 mg and 30 mg), piperacillin/tazobactam (85 mg), cefoxitin (30 mg), imipenem (10 mg), meropenem (10 mg), erythromycin (5 mg), clindamycin (2 mg), tetracycline (10 mg), or metronidazole (5 mg). A small zone was seen surrounding a 10-mg chloramphenicol disc. Metronidazole therapy was stopped, and for the next 5 days the patient continued to receive treatment with piperacillin/tazobactam and chloramphenicol.
Treatment was complicated by Candida guilliermondii fungemia, which required liposomal amphotericin B therapy. The isolation of B. fragilis from intra-abdominal samples persisted, despite laparotomy and abdominal washout. On day 13, treatment with linezolid (600 mg every 12 h) was initiated because the B. fragilis isolates appeared to be sensitive to this agent in vitro. The addition of treatment with linezolid was accompanied by general improvement in several indices of systemic sepsis (i.e., reduction in inotropic and ventilatory requirements and in the serum lactate level) and the failure to isolate any further B. fragilis from intra-abdominal drain or aspiration samples. Despite this improvement, however, the patient developed ischemic bowel disease and died 22 days after admission to the intensive therapy unit.
The anaerobic gram-negative rods retrieved from blood and pus specimens were sent to the National Public Health Service Anaerobe Reference Laboratory in Cardiff (United Kingdom) and confirmed as B. fragilis by 16SrDNA restriction fragmentlength polymorphism analysis [3] . MICs determined by the E test method (AB Biodisk) confirmed simultaneous resistance to b-lactams, b-lactam/inhibitor combinations, carbapenems, macrolides, tetracyclines, and metronidazole, intermediate sensitivity to chloramphenicol, and a linezolid MIC of 1 mg/L (table 1) .
Discussion. Epidemiological studies of the antimicrobial resistance of B. fragilis continue to report high rates of susceptibility (199%) to b-lactam/b-lactamase inhibitor combinations, carbapenems, and metronidazole [4] ; these findings support the use of these agents for surgical prophylaxis and empirical treatment of anaerobic sepsis. Multidrug resistance, especially to both imipenem and metronidazole, has only rarely been described. An isolate with simultaneous resistance to metronidazole, amoxicillin/clavulanate, and imipenem remained susceptible to macrolides and was successfully treated with clindamycin [5] ; thus, to our knowledge, the strain of B. fragilis infecting our patient is the most resistant strain ever encoun- tered in clinical practice because its MICs for amoxycillin/clavulanate, clindamycin, erythromycin, cefoxitin, tetracycline, and metronidazole were all 1256 mg/L, and its MICs for imipenem and meropenem were 132mg/L. The true incidence of the resistance of B. fragilis may be much higher in the U.K., where most laboratories use inhibition to 5 mg of metronidazole as an indication of the presence of obligate anaerobes in a mixed culture [6] , suggesting that the routine recognition of metronidazole-resistant B. fragilis from clinical samples may be suboptimal. Both chromosomal and plasmid mediated resistance determinants have been described in B. fragilis, as have a number of conjugative transposons linked to tetracycline resistance [7] . A unique set of genes, nim A-F, which are associated with resistance to 5-nitroimidazoles, has recently been reported in 24% of 206 Bacteroides species housed in the Anaerobe Reference Laboratory culture collection [8] . Investigations by PCR for nim genes performed at the Anaerobe Reference Laboratory, however, yielded negative results in this case, indicating that other resistance mechanisms remain to be characterized. The prolonged treatment (3 weeks) with metronidazole administered to this patient is a cause for concern, because metronidazole resistance has been known to arise during therapy [9] .
Linezolid, the first of a new class of oxazolidanone antibiotics, is licensed for the treatment of nosocomial pneumonia and soft-tissue infections due to multidrug-resistant gram-positive bacteria. The drug binds to the P site of the bacterial 50s ribosomal subunit, inhibiting protein synthesis. Aerobic gramnegative bacteria are resistant because of efflux mechanisms, but linezolid shows significant activity against gram-negative anaerobes in vitro [10] , with MICs of 2-4 mg/L reported for the B. fragilis group. The patient failed to improve with chloramphenicol therapy, and B. fragilis continued to be isolated from clinical samples, so, although clinical experience with linezolid in the treatment of anaerobic infections is limited, it remained the only viable option for this patient. The agent has excellent bioavailability with a high volume of distribution, enabling penetration into abdominal collections, and it should be considered in cases of drug-resistant anaerobic infection.
